The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Thermo Fisher Scientific Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) The report covers detailed informatio ...

through a tough time that might impact their academic budgets. Thermo Fisher remains cautious since growth could further moderate if the economic scenario worsens. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has moved to $21.65 from $21.64 in the past 30 days. Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS) , Medpace (MEDP) and ResMed (RMD) . Medpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared ...

narvikk Introduction On April 24, I wrote an article covering Alexandria Real Estate Equities (ARE), a REIT that owns healthcare real estate, including laboratories. This REIT is on my radar as a fantastic way to benefit from innovation in healthcare without having to figure out which biotech company will reveal a groundbreaking drug next. [...] the company has provided the facilities that allowed for groundbreaking research, as the company noted that roughly half of all FDA-approved therapies over the past ...

VANCOUVER, BC, May 23, 2024 /PRNewswire/ - Trilogy Metals Inc. (TSX: TMO) (NYSE American: TMQ) ("Trilogy Metals" or the "Company") is pleased to announce the detailed voting results on the items of business considered at its Annual Meeting of Shareholders ("Meeting") held in Vancouver on Wednesday, May 22, 2024. All proposals were approved and the nominees listed in the management proxy circular for the meeting were all elected as directors. A total of 98,964,326 or 61.79% of the Company's issued and outsta ...

Thermo Fisher Scientific (TMO) recently introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, highthroughput assay, supporting future advancements in donor blood matching for extended phenotypes. The latest development is expected to enhance the company's Life Sciences Solutions segment, which off ...

Summary of Thermo Fisher Scientific Inc. Conference Call Company Overview - **Company**: Thermo Fisher Scientific Inc. (NYSE:TMO) - **Event**: Bank of America Securities 2024 Health Care Conference Call - **Date**: May 14, 2024 - **Participants**: Marc Casper (CEO), Mike Ryskin (Bank of America) Industry Insights - **Long-term Industry Growth**: The industry is experiencing strong long-term growth driven by drug pipelines, scientific discoveries, unmet healthcare needs, and advances in technologies such as semiconductors and batteries [4][5] - **Short-term Market Conditions**: The first quarter of 2024 met expectations with predictability in markets. Economic activity is expected to improve modestly throughout the year, supported by China's stimulus program and increased biotech funding [4][5] - **China's Economic Impact**: China is seen as a significant growth market, although growth rates are expected to be lower than in the past decade. A multiyear fiscal stimulus program focused on capital equipment is anticipated to benefit Thermo Fisher's Analytical Instruments segment [10][11][12] Financial Performance and Projections - **2024 Outlook**: The company raised its outlook for the year, expecting modest market improvements and a stronger second half compared to the first half. The guidance implies growth slightly below the normal market conditions of 4% to 6% [6][7][8] - **2025 Expectations**: If current trends continue, 2025 is expected to approach normal market conditions, with growth driven by the pharmaceutical and biotech sectors [6][7] Market Share and Competitive Position - **Market Share Gains**: Thermo Fisher has consistently gained market share, with expectations to grow 2-3 percentage points faster than the market, leading to long-term growth of 7-9% [9][8] - **Bioproduction Business**: The bioproduction segment is recovering with improved order rates and a strong historical track record. The company remains a market leader in cell culture media and single-use technologies [16][17] - **Analytical Instruments Performance**: The Analytical Instruments segment has shown strong results, particularly in electron microscopy and chromatography, benefiting from high-end research demand [19][20] Strategic Initiatives - **CRO and CDMO Expansion**: The acquisition of PPD and Patheon has strengthened Thermo Fisher's position in the biopharma sector, enhancing its end-to-end capabilities and fostering deep collaboration with customers [24][25] - **Capital Deployment Strategy**: The company plans to continue disciplined capital deployment, focusing on M&A opportunities and returning capital to shareholders through dividends and share buybacks [28][30] Geopolitical Considerations - **U.S.-China Relations**: Ongoing geopolitical tensions may affect operations, but Thermo Fisher aims to support customers in navigating these challenges. The company has a strong presence in the West, which may mitigate reliance on China [14][15] Upcoming Events - **Investor Day**: Scheduled for September 19, 2024, to provide a long-term outlook and insights into business performance [32][33] Key Takeaways - **Resilience in Market Conditions**: Despite challenges, Thermo Fisher is well-positioned for growth, with a strong focus on innovation and customer partnerships [34] - **Focus on Long-term Strategy**: The company emphasizes its commitment to delivering consistent results and maintaining investor confidence [34]

Thermo Fisher Scientific Inc. (NYSE:TMO) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team. And I'm thrilled to kick off the Bank of America Las Vegas Healthcare Conference. Joining us f ...

Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is ...

Thermo Fisher Scientific Inc.'s (TMO) first-quarter 2024 adjusted earnings per share (EPS) of $5.11 topped the Zacks Consensus Estimate by 8.7%. The figure also rose 1.6% year over year.The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $3.46, up 4.2% on a year-over-year basis.Revenues in DetailRevenues in the quarter totaled $10.35 billion, down 3.4% year over year. The top line surpassed the Zacks Consensus Estimate ...

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $10.34 billion, with adjusted operating income of $2.28 billion and an adjusted operating margin of 22%, reflecting a 2% year-over-year increase in adjusted EPS to $5.11 per share [49][81] - Adjusted operating income for Specialty Diagnostics increased by 5%, with an adjusted operating margin of 26.5%, which is 120 basis points higher than Q1 2023 [1] - In the Laboratory Products and Biopharma Services segment, both reported revenue and organic growth decreased by 1% in Q1 compared to the prior year quarter, with adjusted operating income declining by 6% and adjusted operating margin at 13% [2] Business Line Data and Key Metrics Changes - Life Sciences Solutions segment reported a 13% decline in revenue, with organic revenue down 12%, driven by lower pandemic-related revenue and activity levels in bioproduction [36] - The Analytical Instruments segment saw a 2% decline in reported revenue and a 1% decrease in organic growth, with strong performance in electron microscopy but unfavorable volume mix impacting margins [71] - The Specialty Diagnostics business experienced flat revenue but strong underlying growth in transplant diagnostics and immunodiagnostics [1] Market Data and Key Metrics Changes - In Q1, North America experienced a mid-single-digit decline, Europe saw a low single-digit decline, and Asia-Pacific and China also declined in the low single-digits [82] - The company expects core organic revenue growth for 2024 to be in the range of minus 1% to positive 1%, with market declines anticipated in low single-digits [3] Company Strategy and Development Direction - The company is raising its 2024 full-year guidance, expecting revenue between $42.3 billion and $43.3 billion, with adjusted EPS in the range of $21.14 to $22.02 [3][4] - The growth strategy focuses on high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine [55] - The company is leveraging its PPI Business System to enhance execution and manage costs effectively while funding long-term investments [4][72] Management's Comments on Operating Environment and Future Outlook - Management noted a modest pickup in economic activity is expected as the year progresses, supported by improvements in the biotech funding environment and a stimulus program announced by China [12][54] - The management expressed confidence in the long-term growth potential of the industry, driven by durable growth from strong science and unmet medical needs [12] - The company is not assuming significant changes in China for the current year but sees potential for growth in 2025 [29] Other Important Information - The company plans to return approximately $600 million to shareholders through dividends and has completed $3 billion in share buybacks [5][34] - The adjusted income tax rate is expected to be 10.5% in 2024, with net capital expenditures projected between $1.3 billion and $1.5 billion [5] Q&A Session Summary Question: How did the quarter progress and what informs the outlook for the balance of the year? - Management indicated that market conditions were in line with expectations, with strong execution leading to financial performance ahead of expectations, allowing for a raised full-year outlook [12] Question: What are the dynamics in the CRO and CDMO businesses? - Management noted strong execution in the clinical research business, with a positive pipeline of activity, although it takes time to materialize into revenues [15] Question: What gives confidence in the biotech funding environment and stimulus in China? - Management highlighted improvements in biotech funding and early stimulus announcements as positive indicators, although they remain cautious about immediate impacts [18][29] Question: How is the performance of analytical instruments, particularly chromatography and mass spectrometry? - Management reported strong performance in electron microscopy and good uptake on new products, despite tough comparisons from the previous year [20] Question: How is the clinical research business performing amidst COVID-related headwinds? - Management confirmed strong growth in clinical research, with no adjustments for COVID impacts, and expects continued momentum in the mid-term [22] Question: How is the company addressing competitive dynamics in pharma services? - Management expressed confidence in their market leadership and high activity levels, indicating a strong position amidst industry changes [24] Question: What is the outlook for the China market and its impact on demand trends? - Management stated that the performance in China met expectations, with no significant changes noted, and they look forward to returning for firsthand insights [39]